Literature DB >> 3789691

Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.

M N Dudley, W C Shyu, C H Nightingale, R Quintiliani.   

Abstract

Previous studies have demonstrated high, concentration-dependent serum protein binding of cefonicid. To determine the in vivo pharmacokinetic significance of these observations, the pharmacokinetics of both total and unbound (non-protein-bound) cefonicid was studied in six volunteers after a single intravenous dose of 30 mg/kg. Saturable serum protein binding was observed in vivo; the mean +/- standard deviation free fraction of cefonicid was 17.6 +/- 6.1% immediately after administration and declined to a constant value of approximately 2% as total serum concentrations fell below 100 micrograms/ml. This nonlinear binding was associated with a pronounced decline in unbound serum cefonicid concentrations during the first 3 h after administration, with low or undetectable unbound drug concentrations by 12 h. Renal clearance of total cefonicid averaged 21.1 ml/min per kg and did not vary with time; in contrast, the mean +/- standard deviation unbound cefonicid renal clearance increased from 5.7 +/- 2.1 to 10.8 +/- 1.6 ml/min per kg with time (P less than 0.02). This study may partially explain the poor results obtained with single daily dosing of cefonicid in endocarditis. Dosage regimens of certain antimicrobial agents with high, saturable serum protein binding and extensive renal tubular secretion may be most appropriately designed based on unbound drug pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3789691      PMCID: PMC176481          DOI: 10.1128/AAC.30.4.565

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Determination of binding constants of serum albumin for penicillin.

Authors:  R W Joos; W H Hall
Journal:  J Pharmacol Exp Ther       Date:  1969-03       Impact factor: 4.030

2.  Effect of saturable binding on the pharmacokinetics of drugs: a simulation.

Authors:  S Oie; T W Guentert; T N Tozer
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

3.  Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.

Authors:  R D Smyth; M Pfeffer; A Glick; D R Van Harken; G H Hottendorf
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

4.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent.

Authors:  C W Stratton; L B Reller
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

6.  Effect of plasma protein binding on renal clearance of drugs.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

Review 7.  Review of cefonicid, a long-acting cephalosporin.

Authors:  M N Dudley; R Quintiliani; C H Nightingale
Journal:  Clin Pharm       Date:  1984 Jan-Feb

8.  Tissue penetration and half-life of cefonicid.

Authors:  C H Nightingale; R Quintiliani; M N Dudley; P Gough; M Hickingbotham; N S Jordan; D Rose; M Toscani
Journal:  Rev Infect Dis       Date:  1984 Nov-Dec

9.  Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis.

Authors:  F M Gengo; T W Mannion; C H Nightingale; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

10.  Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus.

Authors:  H F Chambers; J Mills; T A Drake; M A Sande
Journal:  Rev Infect Dis       Date:  1984 Nov-Dec
View more
  12 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

2.  Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection.

Authors:  M N Dudley; J Blaser; D Gilbert; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 3.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

4.  Effect of age and renal function on cefonicid pharmacokinetics.

Authors:  J M Trang; T P Monson; B H Ackerman; F L Underwood; J T Manning; G L Kearns
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

Review 5.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

7.  Cefonicid versus clindamycin prophylaxis for head and neck surgery in a randomized, double-blind trial, with pharmacokinetic implications.

Authors:  D Swanson; R A Maxwell; J T Johnson; R L Wagner; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Influence of the unbound concentration of cefonicid on its renal elimination in isolated perfused rat kidneys.

Authors:  C A Rodriguez; D E Smith
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

9.  Simultaneous high-performance liquid chromatographic analysis of cefprozil diastereomers in a pharmacokinetic study.

Authors:  W C Shyu; U A Shukla; V R Shah; E A Papp; R H Barbhaiya
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

10.  Applications of minimal physiologically-based pharmacokinetic models.

Authors:  Yanguang Cao; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-23       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.